Immune response and breakthrough infections following an in-label vaccination with Comirnaty against SARS-CoV-2 in the district of Schwaz - Shieldvacc-2

Medizinische Universität Innsbruck, Institut für Virologie0 个研究点目标入组 3,340 人开始时间: 2021年4月29日最近更新: 2022年5月16日

试验速览

暂无简介。

•1.Participant is = 18 years of age on the day of signing the ICF and provides written informed consent
•participant is between 16 and 18 years of age and provides informed consent as well as his/her legal representative/custodial
•2.Subject has been already vaccinated with Comirnaty (two doses), with the second dose having been administered within up to 6 weeks (35 days ± 7 days) before study inclusion
•3.Subject understands and agrees to comply with study procedures
•4.Subject must be willing to be contacted by telephone or willing to complete an eDiary during study participation
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 340
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 2600
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 400

•1.Prior administration of an investigational coronavirus (SARS-CoV, MERS-CoV) vaccine or current/planned simultaneous participation in another interventional study to either prevent or treat COVID-19
•2.Participant has a contraindication to blood draws (eg, bleeding disorders)
•3.Has participated in an interventional clinical study within 30 days prior to study inclusion

发起方

Medizinische Universität Innsbruck, Institut für Virologie